{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:33:31Z","timestamp":1776450811056,"version":"3.51.2"},"reference-count":50,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Protein Science"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite continuous strides forward in drug development, resistance to treatment looms large in the battle against cancer as well as communicable diseases. Chronic myeloid leukemia (CML) is treated with targeted therapy and treatment is personalized when resistance arises. It has been extensively studied and is used as a model for targeted therapy. In this study, we examine combination treatments of type II Abl1 inhibitors and asciminib (an allosteric regulator) through a computational model at patient relevant concentrations. Due to the separate binding sites of type II inhibitors and asciminib, we propose their combination treatment as potentially robust to resistance. We find that the simultaneous cobinding of type II inhibitors and asciminib is high in synergetic combinations. As an aid to designing and comparing combination treatments, we put forward an equation that expands on the previously published effective ratio of IC<jats:sub>50<\/jats:sub> (ERIC). Unlike usual comparisons of IC<jats:sub>50<\/jats:sub> values, ERIC takes patient plasma concentrations into account. This study shows that the product of two ERIC values () creates comparable approximations of the effectiveness of combination treatments with low levels of synergy or antagonism at different concentrations. Its simple formulation is done without experiments and requires less computation and input data than the current standard of ZIP values. As such, the new scheme is a useful complement to experiments that deal with synergy in drug use.<\/jats:p>","DOI":"10.1002\/pro.70219","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T07:54:45Z","timestamp":1752738885000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A computational dynamic model of combination treatment for type <scp>II<\/scp> inhibitors with asciminib"],"prefix":"10.1002","volume":"34","author":[{"given":"J. Roadnight","family":"Sheehan","sequence":"first","affiliation":[{"name":"Department of Mechanical and Industrial Engineering Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid S.","family":"de Wijn","sequence":"additional","affiliation":[{"name":"Department of Mechanical and Industrial Engineering Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biomedical Sciences Linnaeus University  Kalmar Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13257"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00197-7"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5193(05)80266-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18370"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189270"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.88"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02248-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2018.12.004"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.004"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.6b01911"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967536.34543.a6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.25368"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2019.01.011"},{"issue":"9","key":"e_1_2_8_16_1","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti\u2010neoplastic effects on cml cells expressing bcr\u2010abl1 t315i\u2010compound mutations","volume":"11","author":"Gleixner KV","year":"2021","journal-title":"Am J Cancer Res"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0292-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02122-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1990"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1039-z"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.01.028"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1019"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23427"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/CRST.CRST_98_19"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061007"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-016-0108-0"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012300"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.3749.3749"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/2472555217695080"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.4c00049"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16442"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01148-9"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06782-9"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbw104"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403664"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1232163"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-16-8950-5"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1214"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102238"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087057110384402"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00001"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041045"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23338"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1012570"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1312"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1821"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2015.09.001"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.66"}],"container-title":["Protein Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pro.70219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:56:58Z","timestamp":1753797418000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pro.70219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/pro.70219"],"URL":"https:\/\/doi.org\/10.1002\/pro.70219","archive":["Portico"],"relation":{},"ISSN":["0961-8368","1469-896X"],"issn-type":[{"value":"0961-8368","type":"print"},{"value":"1469-896X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"2025-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70219"}}